378 related articles for article (PubMed ID: 35328533)
1. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
3. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
4. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
5. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
6. Advances in the pathogenesis of multiple myeloma bone disease.
Hu C; Kuang C; Zhou W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1403-1410. PubMed ID: 38044652
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Kleber M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2019 Aug; 12(8):651-663. PubMed ID: 31268745
[No Abstract] [Full Text] [Related]
9. Myeloma bone disease: Progress in pathogenesis.
Xi H; An R; Li L; Wang G; Tao Y; Gao L
Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology and therapeutic advances in myeloma bone disease.
Zhang F; Zhuang J
Chronic Dis Transl Med; 2022 Dec; 8(4):264-270. PubMed ID: 36420171
[TBL] [Abstract][Full Text] [Related]
13. New insights in myeloma-induced osteolysis.
Barillé-Nion S; Bataille R
Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
[TBL] [Abstract][Full Text] [Related]
15. The role of bone-modifying agents in myeloma bone disease.
Lu H; Pundole X; Lee HC
JBMR Plus; 2021 Aug; 5(8):e10518. PubMed ID: 34368608
[TBL] [Abstract][Full Text] [Related]
16. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
17. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
18. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
19. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications.
Bernstein ZS; Kim EB; Raje N
Cells; 2022 Jul; 11(15):. PubMed ID: 35954151
[TBL] [Abstract][Full Text] [Related]
20. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
